- Partnership provides worldwide commercial license and supply agreement for enterade®, an amino acidbased,
glucose-free, electrolyte solution designed for oncology and gastrointestinal disease patients
NORWOOD, Mass., November 15, 2018 – Entrinsic Health Solutions (EHS), an innovative health sciences
company, today announced that they have entered into a partnership with Nestlé Health Science (NHSc), a
global innovative leader pioneering premium-quality, science-based nutritional health solutions. The
partnership gives NHSc the exclusive rights to market EHS’s enterade® product.
This partnership is structured as a worldwide commercial license and supply agreement for EHS’s
electrolyte beverage using a patented combination of proprietary amino acids to help address hydration
issues in patients with gastrointestinal (GI) issues related to cancer or chronic GI disease. NHSc has the right
to take over the global commercialization of enterade® following the results of the clinical study of
enterade® in neuroendocrine tumor (NET) patients. Terms of the transaction have not been disclosed.
“We are excited to partner with Nestlé Health Science, a leader in nutritional health solutions that
empower healthier lives. This partnership underscores our commitment to providing disruptive, sciencederived
products utilizing our Amino Acid Coupled-Transport (A₂CT™) technology platform to deliver better
health outcomes in a broad range of therapeutic areas for patients in need of better nutritional support
options. enterade® was designed to address the specific hydration needs of those patients undergoing
cancer treatment or those with chronic GI impairment. We look forward to a long-term and productive
relationship with Nestlé Health Science,” said Stephen J. Gatto, Chairman and CEO of EHS.
Greg Behar, CEO of Nestlé Health Science, stated: “We are pleased to collaborate with Entrinsic Health
Solutions. enterade®’s proprietary blend of scientifically-selected amino acids and electrolytes uniquely
addresses the hydration needs of patients with cancer and chronic GI disease. Clinical studies and inmarket
patient experience confirm the efficacy and benefits that enterade® offers these patient groups.
This partnership underscores our commitment to leading-edge innovation and to providing a
comprehensive range of science-based, nutritional health solutions that enable consumers and patients to
live healthier lives.”
A prospective Phase II study of enterade® in NET and carcinoid syndrome patients with quality-of-life
limiting diarrhea has been initiated and is expected to conclude in 2019. This new study will assess how
enterade® helps patients absorb and retain fluids. A pilot clinical study conducted at the University of
Kentucky Markey Cancer Center demonstrated that daily consumption of enterade® leads to a marked
improvement in patient’s overall quality of life. These results were published in the 2018 ASCO Annual
About Entrinsic Health Solutions
Entrinsic Health Solutions, Inc., is a recognized leader in the development, manufacturing and
commercialization of disruptive, science-derived amino-acid technologies that are clinically-proven to
deliver better health outcomes in a broad range of therapeutic areas including gut health, hydration, skin
and respiratory health. The Company’s proprietary Amino Acid Coupled-Transport (A₂CT™) technology
platform leverages gold-standard science and harnesses game-changing amino acid technology to address
critical health issues. A₂CT™ is a highly customizable transport system for addressing multiple target
conditions and disease states. EHS has ongoing research and development that leverages amino acid
science and technology for consumer health, therapeutics and performance hydration.